EDITORIAL article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicImmune-Checkpoint Inhibitors and Immunometabolic Reprogramming in Cancer ImmunotherapyView all 18 articles
Editorial: Immune-Checkpoint Inhibitors and Immunometabolic Reprogramming in Cancer Immunotherapy
Provisionally accepted
- 1Morehouse School of Medicine, Atlanta, United States
- 2Istituto degli Endotipi in Oncologia Metabolismo e Immunologia G Salvatore, Naples, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
that might also be affected by ICIs [7]. Therefore, the current special issue is designed to understand the roles of ICIs and IR in cancer immunotherapies.This special issue provides a comprehensive overview, from clinical meta-analyses of the esophagus, cervix, melanoma, and NSCLC to mechanistic studies on immunometabolism, microbiota, epigenetics, and cardiovascular toxicity, illustrating the integration of immunology and metabolism in precision cancer medicine with ICIs.The article by Xiong et al. has identified the regulatory role of the NADPH oxidase 4 (NOX4)/MYC axis in murine breast cancer and in immune cell (specifically CD8 + T cells) infiltration, via dysregulation of breast cancer cell metabolism that supports their growth and proliferation, and PD- Moreover, in their breast cancer study, they observed a strong association between higher Hub-UVR.Sig expression (ENO2 or enolase-2 or gamma enolase, critical for glycolysis and gluconeogenesis, and ATP6V1F, which encodes vacuolar ATPase or V-ATPase, mediates acidification of intracellular organelles) and substantial immune evasion and low immunogenicity in patients with worse OS. Thus, understanding the association between UV exposure, ICI treatment, and associated IR is critical to exploring a linkage between UVR and ICI resistance. Furthermore, Yang et al.L1(
Keywords: Cancer, immune-checkpoint inhibitor (ICI), immunometabolic reprogramming, Immunometabolism, immunothera py
Received: 04 Dec 2025; Accepted: 08 Dec 2025.
Copyright: © 2025 KUMAR and De Falco. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: VIJAY KUMAR
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.